Navigation Links
Landmark Findings From ECLIPSE Program Show Improved Control of,Perioperative Hypertension Reduces Risk of Death In Cardiac Surgery

Largest Randomized Safety Program of Intravenous Antihypertensives to Date Presented at ACC Scientific Sessions

NEW ORLEANS, March 27, 2007 /PRNewswire-FirstCall/ -- Findings from ECLIPSE**, the largest safety program comparing intravenous antihypertensive therapies, show that improved control of perioperative hypertension -- a potentially harmful elevation in blood pressure just before, during and/or after surgery - - in patients undergoing cardiac surgery is strongly associated with a reduced risk of death within 30 days following the procedure. The findings were presented at a late-breaking session here at the 56th Annual Scientific Session of the of Cardiology (ACC).

"Perioperative hypertension is a very common problem in cardiac surgery, affecting up to 80 percent of patients," said lead author of the presentation, Solomon Aronson, MD, Duke University Medical Center**. "Findings from ECLIPSE are the first to quantify the relationship between perioperative blood pressure control and clinical outcomes, and demonstrate that better control can dramatically reduce the rate of death in cardiac surgery patients."

"This ECLIPSE analysis contributes to advances in the understanding and treatment of acute hypertension, a condition which affects nearly 3 million people in the U.S. each year," said John Kelley, President and Chief Operating Officer of The Medicines Company. "The Medicines Company is committed to further understanding the importance of better blood pressure control in the acute care setting and we strive to help improve the outcomes of patients who face this life-threatening condition."

Study and Findings

The ECLIPSE program included a total of 1,964 cardiac surgery patients each enrolled in one of three randomized, open-label trials comparing Cleviprex(TM) (clevidipine) to current intravenous antihypertensive agents: nitroglycerin, sodium nitroprusside or nicardipine. Begin ning just before patients went into cardiac surgery, investigators monitored each patient's blood pressure (BP) and administered the assigned antihypertensive agent, at their discretion, if it became too high. Based on each patient's BP response for 24 hours after initiating the therapy, investigators determined "BP excursions" -- how much and how long systolic BP went above or below predefined, acceptable perioperative BP ranges (85-145 mm Hg pre- and post- operatively, and 75-135 mm Hg during surgery).

The analysis showed a statistically significant association between BP excursions and 30-day mortality risk. Specifically, the risk of death increased by 20 percent with an average excursion of just 1 mm Hg/min for 60 minutes, and rose rapidly for each additional 1 mm Hg/min. For instance, an excursion of 5 mm Hg/min for 60 minutes was associated with approximately a 150 percent increased risk of death.

About Perioperative Hypertension

Perioperative hypertension affects patients in the operating room, post- anesthesia care unit and intensive care unit. It is thought to be caused by the rapid shifts in blood volume and increased activity of the sympathetic nervous system that accompany surgery, which in turn increase vasoconstriction, vascular resistance, and both systolic and diastolic BP. The increased pressure can damage blood vessels, resulting in inflammation and leaking of fluid or blood into tissues, and complications such as hemorrhagic stroke, ischemic stroke, encephalopathy, myocardial ischemia or infarction, heart arrhythmia, congestive heart failure, and bleeding at the surgical site.

Perioperative hypertension is treated using intravenous antihypertensive agents, but current therapies have various shortcomings. For example, nitroglycerin and sodium nitroprusside dilate both arteries and veins, which can result in less predictable BP control. Nicardipine is selective for arteries, but because it has a slower onset and longer du ration of action, and accumulates over time in the body, it is rarely used to control BP during surgery, and is only used occasionally after surgery.

About Cleviprex

Cleviprex is a novel, investigational drug rationally designed to meet the needs of the acute care practitioner for an intravenous hypertensive agent. It is the first third-generation dihydropyridine calcium channel blocker that acts rapidly and reliably, is vascular- and arterial- selective, and has an ultrashort half-life. Cleviprex recently completed Phase III clinical trials.


About The Medicines Company

The Medicines Company is committed to delivering innovative, cost- effective acute care products in the worldwide hospital marketplace. The Company markets Angiomax(R) (bivalirudin) in the U.S. and other countries for use in patients undergoing coronary angioplasty, a procedure to clear restricted blood flow in arteries around the heart. The Company also has two products in late-stage development, Cleviprex(TM) (clevidipine) and cangrelor. The Company's website is

Statements contained in this press release about The Medicines Company and Cleviprex that are not purely historical, and all other statements that are not purely historical, may be deemed to be forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Without limiting the foregoing, the words "believes," "anticipates" and "expects" and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties that may cause the Company's actual results, levels of activity, performance or achievements to be materially different from those expressed or implied by these forward-looking statements. Important factors that may cause or contribute to such differences include whether the Company's products will advance in the clinical trials process on a timely basis or at all, whether clinical trial results will warrant submission of applications for regulatory approval, whether the Company will be able to obtain regulatory approvals, whether physicians, patients and other key decision makers will accept clinical trial results, and such other factors as are set forth in the risk factors detailed from time to time in the Company's periodic reports and registration statements filed with the Securities and Exchange Commission including, without limitation, the risk factors detailed in the Company's Annual Report on Form 10-K filed on March 1, 2007, which are incorporated herein by reference. The Company specifically disclaims any obligation to update these forward-looking statements.

    * Evaluation of CLevidipine In the Postoperative Treatment of Hypertension

      Assessing Safety Events

    ** Dr. Solomon Aronson is a paid consultant for The Medicines Company

CONTACT: Media - Jackie Krieger Biosector 2 +1-212-845-5612 Investors - Michael Mitchell Executive Director,Corporate Affairs The Medicines Company +1-973-656-1616

Web site:

Ticker Symbol: (:MDCO)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


Related medicine technology :

1. Neurologix Announces Publication of Landmark Gene Therapy Study Demonstrating Safety and Statistically Significant Improvement in Patients With Advanced Parkinsons Disease
2. MEDIA ADVISORY: Subsets of Landmark Diabetes Trials Investigating MacroVascular Outcomes Presented at the American Diabetes Association 67th Scientific Sessions
3. Geron Corp. Licensee TA Sciences Announces Landmark 7/07/07 Teleconference to Answer Questions About TA-65, Their Telomerase Activator With Proven Age Management Benefits
4. Landmark Study Published in the New England Journal of Medicine Shows Important Benefits of Eprodisate (KIACTA) Treatment for Patients with Amyloid A (AA) Amyloidosis
5. Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events in Landmark Jikei Heart Study
6. Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events in Landmark Jikei Heart Study
7. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
8. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
9. Molecular Target of Bradmers Neuradiab Further Validated by Independent Findings
10. Anacor Identifies a Novel Mechanism for Its Lead Anti-Fungal Drug, AN2690; Findings Published in Science
11. Advanced Viral Research Corp. Announces Positive Preliminary Findings from Ongoing Phase II Dermatological Study
Post Your Comments:
(Date:11/26/2015)... Nederland, November 26, 2015 ... Een nieuwe aanpak combineert immunotherapie met Bremachlorin-photodynamische ... ) --> ...      (Photo: ) ... Universitair Medisch Centrum (LUMC) blijkt ...
(Date:11/26/2015)... Nov. 26, 2015 Research and Markets ... the "2016 Future Horizons and Growth Strategies ... Supplier Shares, Country Segment Forecasts, Competitive Intelligence, Emerging ... --> --> This ... the Japanese therapeutic drug monitoring market, including emerging ...
(Date:11/26/2015)... 2015 --> ... potential att använda SyMRI för att hitta ... patienter med multipel skleros (MS) eller hjärntumörmetastaser ... AB för att kunna använda SyMRI Research ... SyMRI kan man generera flera konstrastbilder från ...
Breaking Medicine Technology:
(Date:11/27/2015)... Canada (PRWEB) , ... November 28, 2015 , ... There ... do we outperform our billings from last year? , This question has not been ... organizations are coming to the retirement age and the younger workforce don’t share the ...
(Date:11/27/2015)... ... November 27, 2015 , ... The rapid ... America. As people age, more care is needed, especially with Alzheimer’s, dementia and ... professionals are being overworked. The forgotten part of this equation: 80 percent of ...
(Date:11/27/2015)... ... November 27, 2015 , ... Lizzie’s Lice Pickers just announced a special ... 10% off of their purchase of lice treatment product. In addition, customers will receive ... a company spokesperson. “Finding lice is a sure way to ruin the holidays, so ...
(Date:11/27/2015)... ... November 27, 2015 , ... Consistent with the ... 2016 Building Better Radiology Marketing Programs meeting will showcase some of ... 6, 2016, at Caesars Palace in Las Vegas with a pre-conference session on ...
(Date:11/27/2015)... ... November 27, 2015 , ... Keeping in mind challenges faced ... and wellness consultation, has collaborated with a leading web-based marketplace for extra-curricular activities ... by parents and bring advice from parenting experts within their reach. As a ...
Breaking Medicine News(10 mins):